Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 20:05 | 2026-04-14 | TWST | Twist Bioscience Corp | Laponis Adam | Officer | SELL | $55.00 | 3,000 | $165,000 | 122,694 |
| 2026-04-16 23:36 | 2026-04-14 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $14.45 | 57,180 | $826,251 | 408,160 |
| 2026-04-16 22:40 | 2026-04-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | SELL | $140.96 | 3,000 | $422,880 | 128,779 |
| 2026-04-16 22:41 | 2026-04-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer | SELL | $140.96 | 3,000 | $422,880 | 176,191 |
| 2026-04-16 22:49 | 2026-04-16 | AURA | Aura Biosciences, Inc. | Kilroy Conor | Officer | SELL | $7.02 | 11,738 | $82,401 | 217,835 |
| 2026-04-16 22:30 | 2026-04-14 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer | OPT+S | $90.00 | 6,551 | $589,599 | 61,202 |
| 2026-04-16 22:30 | 2026-04-14 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Officer | SELL | $90.00 | 1,347 | $121,230 | 50,195 |
| 2026-04-16 22:16 | 2026-04-14 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Director | OPT+S | $90.01 | 9,494 | $854,539 | 674,956 |
| 2026-04-15 21:29 | 2026-04-13 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $16.10 | 737,989 | $11,883,320 | 3,197,619 |
| 2026-04-15 20:07 | 2026-04-14 | CGEN | COMPUGEN LTD | Levine Zurit | Officer | OPT+S | $2.80 | 2,000 | $5,600 | 29,375 |
| 2026-04-15 20:10 | 2026-04-14 | CGEN | COMPUGEN LTD | Ophir Eran | Director, Officer | OPT+S | $2.90 | 5,000 | $14,521 | 11,375 |
| 2026-04-15 20:05 | 2026-04-14 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Director, Officer | SELL | $17.64 | 8,000 | $141,125 | 605,471 |
| 2026-04-14 21:00 | 2026-04-13 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | Officer | OPT+S | $6.41 | 33,171 | $212,759 | 49,849 |
| 2026-04-13 23:44 | 2026-04-09 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $13.26 | 57,180 | $758,110 | 421,174 |
| 2026-04-13 21:00 | 2026-04-10 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | Director, Officer, 10% owner | OPT+S | $6.43 | 124,727 | $802,494 | 436,422 |
| 2026-04-13 21:00 | 2026-04-10 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% owner | OPT+S | $6.43 | 124,727 | $802,494 | 436,422 |
| 2026-04-13 20:33 | 2026-04-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Director, Officer | OPT+S | $4.46 | 200,000 | $892,000 | 1,136,410 |
| 2026-04-13 20:04 | 2026-04-10 | CGEN | COMPUGEN LTD | Levine Zurit | Officer | OPT+S | $2.56 | 3,125 | $8,013 | 29,375 |
| 2026-04-13 20:05 | 2026-04-09 | TWST | Twist Bioscience Corp | Laponis Adam | Officer | SELL | $49.89 | 2,597 | $129,562 | 125,694 |
| 2026-04-13 11:19 | 2026-04-04 | MESO | MESOBLAST LTD | George Gregory | Director, 10% owner | BUY | $1.44 | 7,910,962 | $11,397,323 | 8,324,072 |
| 2026-04-11 00:00 | 2026-04-08 | APGE | Apogee Therapeutics, Inc. | HENDERSON MICHAEL THOMAS | Director, Officer | SELL | $82.58 | 20,000 | $1,651,664 | 1,132,987 |
| 2026-04-10 23:27 | 2026-04-04 | MESO | MESOBLAST LTD | George Gregory | Director, 10% owner | BUY | $3.15 | 8,305,962 | $26,134,709 | 8,324,072 |
| 2026-04-10 22:52 | 2026-04-08 | ADPT | Adaptive Biotechnologies Corp | LO FRANCIS | Officer | OPT+S | $15.07 | 22,564 | $340,039 | 271,154 |
| 2026-04-10 22:48 | 2026-04-08 | ADPT | Adaptive Biotechnologies Corp | ROBINS HARLAN S | Officer | SELL | $14.85 | 10,000 | $148,500 | 1,512,058 |
| 2026-04-10 22:23 | 2026-04-08 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $16.50 | 620,133 | $10,233,807 | 3,935,608 |
| 2026-04-10 21:01 | 2026-04-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | Director, Officer | OPT+S | $6.65 | 206,782 | $1,374,501 | 316,483 |
| 2026-04-10 21:01 | 2026-04-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% owner | OPT+S | $6.66 | 26,271 | $175,067 | 338,568 |
| 2026-04-10 21:02 | 2026-04-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | Director, Officer, 10% owner | OPT+S | $6.66 | 26,271 | $175,067 | 338,568 |
| 2026-04-10 20:45 | 2026-04-09 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Officer | OPT+S | $87.47 | 10,264 | $897,782 | 51,542 |
| 2026-04-10 20:30 | 2026-04-08 | EXOZ | EXOZYMES INC. | Korman Tyler Paz | Officer | SELL | $10.28 | 1,500 | $15,424 | 729,123 |
| 2026-04-10 20:07 | 2026-04-09 | GLUE | Monte Rosa Therapeutics, Inc. | Nickson Philip | Officer | SELL | $17.69 | 5,845 | $103,413 | 55,000 |
| 2026-04-10 20:02 | 2026-04-08 | IMVT | Immunovant, Inc. | Stout Jay S | Officer | SELL | $24.83 | 10,132 | $251,578 | 254,439 |
| 2026-04-10 20:03 | 2026-04-08 | IMVT | Immunovant, Inc. | Gloria Melanie | Officer | SELL | $24.83 | 8,722 | $216,567 | 245,222 |
| 2026-04-10 20:05 | 2026-04-08 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | Officer | SELL | $24.83 | 5,165 | $128,247 | 183,231 |
| 2026-04-10 00:55 | 2026-04-07 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | Officer | OPT+S | $13.19 | 19,517 | $257,498 | 213,867 |
| 2026-04-09 21:25 | 2026-04-08 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Officer | SELL | $5.40 | 1,134 | $6,124 | 94,827 |
| 2026-04-09 20:05 | 2026-04-07 | CGEN | COMPUGEN LTD | Levine Zurit | Officer | OPT+S | $2.38 | 7,875 | $18,757 | 29,375 |
| 2026-04-08 23:48 | 2026-04-06 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $14.34 | 69,061 | $990,500 | 434,188 |
| 2026-04-08 23:51 | 2026-04-06 | ADPT | Adaptive Biotechnologies Corp | ROBINS CHAD M | Director, Officer | SELL | $14.65 | 120,595 | $1,766,837 | 2,180,518 |
| 2026-04-08 20:58 | 2026-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | SELL | $3.10 | 30,000 | $93,000 | 6,229,863 |
| 2026-04-08 20:58 | 2026-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | SELL | $3.10 | 40,000 | $124,000 | 906,556 |
| 2026-04-08 20:32 | 2026-04-07 | PCVX | Vaxcyte, Inc. | Cowan Elvia | Officer | OPT+S | $60.00 | 3,000 | $180,000 | 28,975 |
| 2026-04-08 00:57 | 2026-04-07 | MGTX | MeiraGTx Holdings plc | Naylor Stuart | Officer | SELL | $9.36 | 27,661 | $258,907 | 668,505 |
| 2026-04-07 21:13 | 2026-04-06 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $63.50 | 10,000 | $634,982 | 767,780 |
| 2026-04-07 20:55 | 2026-04-06 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | Director, Officer | SELL | $5.69 | 55,000 | $313,137 | 340,106 |
| 2026-04-07 20:50 | 2026-04-06 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | Director, Officer | SELL | $9.16 | 72,559 | $664,350 | 948,145 |
| 2026-04-06 22:51 | 2026-04-02 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $17.10 | 849,257 | $14,518,983 | 4,555,741 |
| 2026-04-06 21:39 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | Officer | SELL | $24.58 | 5,956 | $146,398 | 109,711 |
| 2026-04-06 21:39 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | Officer | SELL | $24.58 | 3,242 | $79,688 | 51,171 |
| 2026-04-06 21:44 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Officer | SELL | $24.58 | 6,700 | $164,686 | 102,735 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.